专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010032123A1 TRITERPENOID COMPOUNDS AND METHODS OF USE THEREOF 审中-公开
标题翻译： TRITERPENOID化合物及其使用方法
公开(公告)号：WO2010032123A1
公开(公告)日：2010-03-25
申请号：PCT/IB2009/006894
申请日：2009-09-19
申请人： BIOTECHNOLOGY RESEARCH CORPORATION LIMITED , IP, Nancy Yuk-Yu , IP, Fanny Chui-Fun , HU, Yueqing
发明人： IP, Nancy Yuk-Yu , IP, Fanny Chui-Fun , HU, Yueqing
IPC分类号： C07J63/00 , A61K31/56 , A61P25/04 , A61P25/14 , A61P25/22 , A61P25/28 , A61P37/02
CPC分类号： C07J63/00 , A61K31/56
摘要： The present invention provides therapeutically active compounds and compositions as receptor antagonists and methods of use thereof. In one aspect, the compounds are useful in modulating pain, inflammation and acute phase reactions by inhibiting the PGE2 receptors including PGE2 EP1, EP2 and EP4 receptors.
摘要翻译：本发明提供治疗活性化合物和作为受体拮抗剂的组合物及其使用方法。在一个方面，该化合物可用于通过抑制PGE2受体包括PGE2 EP1，EP2和EP4受体来调节疼痛，炎症和急性期反应。

2. 发明申请

WO1997029770A1 SARCOCYSTIS VACCINE 审中-公开
公开(公告)号：WO1997029770A1
公开(公告)日：1997-08-21
申请号：PCT/AU1996000419
申请日：1996-07-05
申请人： SARCO RESEARCH CORPORATION LIMITED , AZUMENDI, Jose Luis
发明人： SARCO RESEARCH CORPORATION LIMITED
IPC分类号： A61K39/002
CPC分类号： A61K39/002
摘要： The present invention relates to a vaccine for immunisation against infections produced by Sarcocystis protozoa comprising lyophilised inactivated bradozooids of the Sarcocystis protozoa and a pharmaceutically acceptable carrier therefor. The present invention also relates to a method for producing the vaccine.
摘要翻译：本发明涉及一种用于针对由包括Sarcocystis原虫的冻干灭活的Bradozooid的Sarcocystis protozoa产生的感染免疫的疫苗及其药学上可接受的载体。本发明还涉及疫苗的制造方法。

3. 发明申请

WO1989000696A1 ANTENATAL SCREENING FOR DOWN'S SYNDROME 审中-公开
标题翻译：对下来的综合征的ANTNATAL筛选
公开(公告)号：WO1989000696A1
公开(公告)日：1989-01-26
申请号：PCT/GB1988000557
申请日：1988-07-11
申请人： RESEARCH CORPORATION LIMITED , WALD, Nicholas, John , CUCKLE, Howard, Stephen , CANICK, Jacob, Abraham , HADDOW, James, Edward
发明人： RESEARCH CORPORATION LIMITED
IPC分类号： G01N33/74
CPC分类号： G01N33/689 , G01N33/743 , G01N33/76 , G01N2800/387
摘要： An antenatal screening test for risk of Down's Syndrome in a foetus, which is carried out on a maternal blood sample before the beginning of the third trimester of pregnancy, comprises assaying the sample for a metabolite of feto-placental activity which is affected by the presence of Down's Syndrome, and which may be selected from unconjugated oestriol; progesterone; 16-alpha-hydroxy-dehydroepiandrosterone sulphate (16-alpha-hydroxy-DHEAS); and, dehydroepiandrosterone sulphate (DHEAS). The method may also include an additional assay for alpha-fetoprotein and/or human chorionic gonadotrophin.
摘要翻译：在妊娠前三孕期开始的孕妇血液样品中进行胎儿唐氏综合征风险的产前筛查试验包括测定样品中胎盘活性的代谢物，其受到存在的影响的唐氏综合征，其可以选自未缀合的雌三醇; 孕激素; 16-α-羟基 - 脱氢表雄酮硫酸酯（16-α-羟基-DEEAS）; 和脱氢表雄酮硫酸盐（DHEAS）。该方法还可以包括甲胎蛋白和/或人绒毛膜促性腺激素的另外的测定。

4. 发明申请

WO1988007047A1 INOSITOL PHOSPHATE ANALOGUES 审中-公开
标题翻译： INOSITOL磷酸酯类似物
公开(公告)号：WO1988007047A1
公开(公告)日：1988-09-22
申请号：PCT/GB1988000186
申请日：1988-03-10
申请人： RESEARCH CORPORATION LIMITED , POTTER, Barry, Victor, Lloyd
发明人： RESEARCH CORPORATION LIMITED
IPC分类号： C07F09/177
CPC分类号： C07F9/177 , Y02P20/55
摘要： Novel inositol phosphorothioates have the general formula (I) C6H6(OH)n[(OPO2S) ]m[(OPO2O) ]6-m-n in which n is zero or an integer from 1 to 5 and, m is an integer from 1 to 6. They may be prepared by a method comprising reacting an inositol derivative having the general formula (II) C6H6(OB)n[OP(OCH2CH2CN)2]6-n in which n is zero or an integer from 1 to 5 and B represents a hydroxyl-protecting group, with a solution of elemental sulphur, which may or may not be radioactive, in a solvent therefor, and removing the hydroxyl-protecting groups from the product of the reaction. Phosphate esters may be prepared by oxidising the compound of formula (II) with an organic peroxide.
摘要翻译：新的肌醇硫代磷酸酯具有通式（I）C 6 H 6（OH）n [（OPO 2 S）2 - ] m [（OPO 2 O）2 - ]] 6-nn，其中n为0或1至5的整数， m为1〜6的整数。它们可以通过包括使具有通式（II）的C6H6（OB）n [OP（OCH2CH2CN）2] 6-n的肌醇衍生物与其中n为0或 B为1〜5的整数，B表示羟基保护基，在其溶剂中可含或不具有放射性的元素硫溶液，并从反应产物中除去羟基保护基。磷酸酯可以通过用有机过氧化物氧化式（II）的化合物来制备。

5. 发明申请

WO1987005885A1 PLANT PACKAGE 审中-公开
标题翻译：工厂包装
公开(公告)号：WO1987005885A1
公开(公告)日：1987-10-08
申请号：PCT/GB1987000218
申请日：1987-04-01
申请人： RESEARCH CORPORATION LIMITED , CASSELLS, Alan, Condon
发明人： RESEARCH CORPORATION LIMITED
IPC分类号： B65D85/52
CPC分类号： B65D85/52 , B65D81/263 , B65D2565/388
摘要： A package (1) for the production and/or storage of plants, comprising a sealed container (2) for the plants in which at least a portion of the container is a membrane assembly of at least two selectively permeable membrane layers, an innermost membrane (5) having relatively high permeability to both gases and water vapour and an outermost membrane (6) having relatively high permeability to gases but being substantially impermeable to water vapour, said outer membrane layer (6) being strippable from the package leaving the innermost membrane (5) intact.

6. 发明申请

WO2011114220A1 NEURO-PROTECTIVE EFFECTS OF ADELOSTEMMA GRACILLIMUM AND ITS ISOLATED COMPOUNDS 审中-公开
标题翻译：阿尔卑斯山楂及其分离化合物的神经保护作用
公开(公告)号：WO2011114220A1
公开(公告)日：2011-09-22
申请号：PCT/IB2011/000567
申请日：2011-03-18
申请人： BIOTECHNOLOGY RESEARCH CORPORATION LIMITED , IP, Nancy, Yuk-yu , IP, Fanny, Chui-Fun , GUO, Shengjun
发明人： IP, Nancy, Yuk-yu , IP, Fanny, Chui-Fun , GUO, Shengjun
IPC分类号： A61K31/085 , A61K31/357 , A61K31/065 , A61K31/343 , A61K31/56 , A61K31/22 , A61K31/215 , A61K36/27 , C07C43/243 , C07D319/20 , C07C31/20 , C07D307/78 , C07C69/738 , C07C69/003 , C07J1/00 , A61P25/00 , A61P25/28 , A61P25/08
CPC分类号： C07J17/005 , A61K31/01 , A61K31/015 , A61K31/045 , A61K31/05 , A61K36/27 , A61K36/896 , A61K36/906 , C07C43/23 , C07C49/83 , C07C59/90 , C07C62/32 , C07C2602/10 , C07D307/79 , C07D307/80 , C07D319/20 , C07H7/04 , C07H7/06 , C07J63/008
摘要： Isolated compounds from adelostemma gracillimum refined fractions and compositions containing the compounds are provided by the present invention. Adelostemma gracillimum refined fractions and the extraction process thereof are also provided by the present invention. The uses of the compounds and the adelostemma gracillimum refined fractions for inhibiting the activities of NMDA receptor or amyloid-beta peptide, for improving memory, and for treating neurodegenerative diseases, neuropathological conditions or epilepsy are further provided by the present invention.
摘要翻译：通过本发明提供了来自adelostemma gracillimum精制级分的分离化合物和含有这些化合物的组合物。本发明还提供了最佳精制级分及其提取方法。通过本发明进一步提供了化合物和adelostemma gracillimum精制级分用于抑制NMDA受体或淀粉样蛋白-β肽的活性，用于改善记忆和治疗神经变性疾病，神经病理学病症或癫痫的用途。

7. 发明申请

WO1989003696A1 BLOOD PURIFICATION APPARATUS 审中-公开
标题翻译：血液净化装置
公开(公告)号：WO1989003696A1
公开(公告)日：1989-05-05
申请号：PCT/GB1988000920
申请日：1988-10-21
申请人： RESEARCH CORPORATION LIMITED , GREENWOOD, Roger, Newton , ALDRIDGE, Colin , TATTERSALL, James, Erskine , BARRETT, Rodney, Valentine
发明人： RESEARCH CORPORATION LIMITED
IPC分类号： A61M01/30
CPC分类号： A61M1/30 , A61M1/1006 , A61M1/1037 , A61M1/1063 , A61M1/1698 , A61M1/303 , A61M1/308 , A61M1/3434 , A61M1/3437 , A61M1/3604 , A61M1/3679 , A61M5/1486
摘要： Blood purification apparatus comprises a dead-end system in which blood from the patient is allowed to flow through one or more purification modules (4), such as a dialyser, a haemofilter, a haemoperfusion column and an oxygenator, into a resiliently walled reservoir (6), which is conveniently a standard blood bag. The direction of flow of the blood is then reversed by exertion of sufficient pressure on the bag (6) to push the blood back through the purification module (4) to the patient's circulation. Thus, since the reservoir is of variable capacity, being of resilient material for example, the capacity of the apparatus remains equal to the volume of extra-corporeal blood.
摘要翻译：血液净化装置包括死端系统，其中允许来自患者的血液通过一个或多个净化模块（例如透析器，血液滤过器，血液灌注柱和充氧器）流入弹性壁储存器，这是方便的一个标准血袋。然后通过在袋上施加足够的压力来逆转血液的流动方向，以将血液通过净化模块推回患者的循环。因此，由于储存器具有可用容量，例如具有弹性材料，装置的容量保持等于体外血液的体积。

8. 发明申请

WO1988009321A1 SUBSTITUTED PHENONE 审中-公开
标题翻译：取代的PHENONE
公开(公告)号：WO1988009321A1
公开(公告)日：1988-12-01
申请号：PCT/GB1988000406
申请日：1988-05-23
申请人： RESEARCH CORPORATION LIMITED , MORRIS, Howard, Redfern , KAY, Robert, Roger , MASENTO, Mark, Steven , TAYLOR, Graham, Walter
发明人： RESEARCH CORPORATION LIMITED
IPC分类号： C07C49/84
CPC分类号： C07C49/84 , C07C45/00 , C07C45/42 , C07C45/54 , C07C49/825 , C07C49/83 , C07C49/835
摘要： A compound which has the biological action of inducing cell differentiation has general chemical formula (I), in which R1 is a straight or branched chain or cyclic alkyl or alkenyl group; R2 is an alkoxy or hydroxy group; R3 is a hydrogen or halogen atom; and, R4 is a halogen atom. Preferred values for the groups are R1 = C3 to C8 alkyl; R2 = methoxy; and, either or both of R3 and R4 = chlorine. The compounds: 1) 2,6-dihydroxy-3,5-dichloro-4-methoxy valerophenone; 2) 2,6-dihydroxy-3,5-dichloro-4-methoxy butyrophenone; and, 3) 2,6-dihydroxy-3-chloro-4-methoxy valerophenone are of particular interest.
摘要翻译：具有诱导细胞分化的生物学作用的化合物具有通式（I），其中R 1为直链或支链或环状烷基或链烯基; R2是烷氧基或羟基; R3是氢或卤原子; R4为卤素原子。基团的优选值为R 1 = C 3至C 8烷基; R2 =甲氧基; 并且R 3和R 4之一或两者均为氯。化合物：1）2,6-二羟基-3,5-二氯-4-甲氧基缬草酮; 2）2,6-二羟基-3,5-二氯-4-甲氧基丁酰苯; 和，3）2,6-二羟基-3-氯-4-甲氧基缬草酮是特别感兴趣的。

9. 发明申请

WO1988007054A1 COMPLEMENT-BINDING PEPTIDE 审中-公开
标题翻译：补充结合肽
公开(公告)号：WO1988007054A1
公开(公告)日：1988-09-22
申请号：PCT/GB1988000213
申请日：1988-03-18
申请人： RESEARCH CORPORATION LIMITED , WINTER, Gregory, Paul , DUNCAN, Alexander, Robert
发明人： RESEARCH CORPORATION LIMITED
IPC分类号： C07K07/00
CPC分类号： C07K16/00
摘要： A polypeptide, having the ability to inhibit complement mediated lysis, consists of or contains the amino acid sequence (I): -X-A-Y-A-Z-, in which X is a polar amino acid, A is any amino acid; Y is a basic amino acid, and Z is a basic amino acid. In a preferred embodiment the polypeptide has the general formula (II): Head-X-A-Y-A-Z-Tail, in which X is Asn, Glu, Thr or Gln, Y and Z are, independently, Lys or Arg, 'Head' is a hydrogen atom or a sequence of amino acid residues attached to the amino group of the adjacent amino acid X, 'Tail' is a hydrogen atom or a sequence of amino acid residues attached to the carboxyl group of the adjacent amino acid Y, and, each of the groups represented by A, which may be the same or different, is an amino acid residue.
摘要翻译：具有抑制补体介导的裂解能力的多肽由X或A-Y-A-Z-组成或含有其中X为极性氨基酸的氨基酸序列（I），A为任何氨基酸; Y是碱性氨基酸，Z是碱性氨基酸。在优选的实施方案中，多肽具有通式（II）：头XAYAZ-尾，其中X是Asn，Glu，Thr或Gln，Y和Z独立地是Lys或Arg，'头'是氢原子或连接于相邻氨基酸X的氨基的氨基酸残基的序列，“尾”是与相邻氨基酸Y的羧基相连的氢原子或氨基酸残基的序列，由A表示的可以相同或不同的基团是氨基酸残基。

10. 发明申请

WO1988001254A1 MODIFICATION OF ZEOLITES 审中-公开
标题翻译： ZEOLITES的修改
公开(公告)号：WO1988001254A1
公开(公告)日：1988-02-25
申请号：PCT/GB1987000591
申请日：1987-08-21
申请人： RESEARCH CORPORATION LIMITED , REES, Lovat, Victor, Charles , LEE, Edward, Fook, Tin
发明人： RESEARCH CORPORATION LIMITED
IPC分类号： C01B33/28
CPC分类号： C01B33/2884 , B01J29/04 , B01J29/084 , B01J2229/16 , B01J2229/183 , B01J2229/32 , B01J2229/34 , C01B35/1009 , C01B39/026 , C10G11/05
摘要： A method for the modification of the framework structure of a zeolite comprises treating the zeolite with a solution in an organic solvent of a compound of an element capable of structural remplacement of aluminium in the framework, the aluminium-replacing element being selected from, for example, boron, tin, silicon, titanium, germanium, gallium, phosphorus, beryllium and magnesium preferably in the form of their halides or organometallic compounds. Typical compounds are BCl3, BBr3, SnCl4, SnBr4, SnI4, SiCl4, SiI4, TiCl4, GeCl4, GaCl4, PCl5, BeCl2, MgCl2 and beryllium diphenyl. In a preferred embodiment the zeolite is reacted with silicon tetrachloride in carbon tetrachloride under reflux. However, the reaction time can be reduced by utilizing a solvent which has a molecular size which prevents it entering the channels of the zeolite, one such solvent being tetraethoxysilane.
摘要翻译：用于改性沸石的骨架结构的方法包括用在框架中能够结构地重新置换铝的元素的化合物的有机溶剂中的溶液处理沸石，铝替代元件例如选自，硼，锡，硅，钛，锗，镓，磷，铍和镁以其卤化物或有机金属化合物的形式。典型的化合物是BCl3，BBr3，SnCl4，SnBr4，SnI4，SiCl4，SiI4，TiCl4，GeCl4，GaCl4，PCl5，BeCl2，MgCl2和铍二苯。在优选的实施方案中，沸石在四氯化碳中在回流下与四氯化硅反应。然而，可以通过利用具有防止其进入沸石通道的分子尺寸的溶剂来降低反应时间，一种这样的溶剂是四乙氧基硅烷。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式